Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
The company's comparison of its ADCs to Enhertu seems farfetched.
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
